CA2496251A1 - High-throughput assay of hematopoietic stem and progenitor cell proliferation - Google Patents
High-throughput assay of hematopoietic stem and progenitor cell proliferation Download PDFInfo
- Publication number
- CA2496251A1 CA2496251A1 CA002496251A CA2496251A CA2496251A1 CA 2496251 A1 CA2496251 A1 CA 2496251A1 CA 002496251 A CA002496251 A CA 002496251A CA 2496251 A CA2496251 A CA 2496251A CA 2496251 A1 CA2496251 A1 CA 2496251A1
- Authority
- CA
- Canada
- Prior art keywords
- kit
- cell
- cells
- interleukin
- target cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 121
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 119
- 238000012203 high throughput assay Methods 0.000 title claims abstract description 26
- 230000004663 cell proliferation Effects 0.000 title description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 480
- 238000000034 method Methods 0.000 claims abstract description 152
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 137
- 230000002062 proliferating effect Effects 0.000 claims abstract description 97
- 238000004020 luminiscence type Methods 0.000 claims abstract description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 230000003834 intracellular effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 104
- 230000001332 colony forming effect Effects 0.000 claims description 80
- 102000004127 Cytokines Human genes 0.000 claims description 79
- 108090000695 Cytokines Proteins 0.000 claims description 79
- 102000000646 Interleukin-3 Human genes 0.000 claims description 54
- 108010002386 Interleukin-3 Proteins 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 46
- 238000012544 monitoring process Methods 0.000 claims description 40
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 39
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 39
- 229920000609 methyl cellulose Polymers 0.000 claims description 37
- 239000001923 methylcellulose Substances 0.000 claims description 37
- 235000010981 methylcellulose Nutrition 0.000 claims description 37
- 239000003102 growth factor Substances 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 34
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 32
- 230000035755 proliferation Effects 0.000 claims description 32
- 210000002960 bfu-e Anatomy 0.000 claims description 29
- 239000002609 medium Substances 0.000 claims description 29
- 229940076264 interleukin-3 Drugs 0.000 claims description 28
- 102000004889 Interleukin-6 Human genes 0.000 claims description 26
- 108090001005 Interleukin-6 Proteins 0.000 claims description 26
- 229940100601 interleukin-6 Drugs 0.000 claims description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 23
- 210000001185 bone marrow Anatomy 0.000 claims description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 22
- 102100021592 Interleukin-7 Human genes 0.000 claims description 21
- 108010002586 Interleukin-7 Proteins 0.000 claims description 21
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 21
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 21
- 229940100994 interleukin-7 Drugs 0.000 claims description 21
- 102000003951 Erythropoietin Human genes 0.000 claims description 20
- 108090000394 Erythropoietin Proteins 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 229940105423 erythropoietin Drugs 0.000 claims description 20
- 210000002540 macrophage Anatomy 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 19
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 19
- 210000003013 erythroid precursor cell Anatomy 0.000 claims description 19
- 210000002966 serum Anatomy 0.000 claims description 19
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 18
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 18
- 102000036693 Thrombopoietin Human genes 0.000 claims description 18
- 108010041111 Thrombopoietin Proteins 0.000 claims description 18
- 239000012091 fetal bovine serum Substances 0.000 claims description 18
- 231100000226 haematotoxicity Toxicity 0.000 claims description 17
- 210000005259 peripheral blood Anatomy 0.000 claims description 17
- 239000011886 peripheral blood Substances 0.000 claims description 17
- 102000000588 Interleukin-2 Human genes 0.000 claims description 15
- 108010002350 Interleukin-2 Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 13
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 13
- 210000003593 megakaryocyte Anatomy 0.000 claims description 13
- 102000004877 Insulin Human genes 0.000 claims description 12
- 230000000925 erythroid effect Effects 0.000 claims description 12
- 210000003714 granulocyte Anatomy 0.000 claims description 12
- 229940125396 insulin Drugs 0.000 claims description 12
- -1 stem cell factor Proteins 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 11
- 239000012298 atmosphere Substances 0.000 claims description 11
- 102000003812 Interleukin-15 Human genes 0.000 claims description 10
- 108090000172 Interleukin-15 Proteins 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 claims description 10
- 239000002458 cell surface marker Substances 0.000 claims description 10
- 210000004700 fetal blood Anatomy 0.000 claims description 10
- 102000000589 Interleukin-1 Human genes 0.000 claims description 9
- 108010002352 Interleukin-1 Proteins 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 239000006285 cell suspension Substances 0.000 claims description 9
- 230000004069 differentiation Effects 0.000 claims description 9
- 238000000684 flow cytometry Methods 0.000 claims description 9
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000002054 transplantation Methods 0.000 claims description 8
- 206010061188 Haematotoxicity Diseases 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000014429 Insulin-like growth factor Human genes 0.000 claims description 5
- 102100039897 Interleukin-5 Human genes 0.000 claims description 5
- 108010002616 Interleukin-5 Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 5
- 229940100602 interleukin-5 Drugs 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 210000001325 yolk sac Anatomy 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 4
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 4
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims description 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 4
- 239000005089 Luciferase Substances 0.000 claims description 4
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 4
- 101150052863 THY1 gene Proteins 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 102100035716 Glycophorin-A Human genes 0.000 claims description 3
- 108091005250 Glycophorins Proteins 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 102100040120 Prominin-1 Human genes 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 230000011132 hemopoiesis Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 239000012086 standard solution Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 72
- 238000012216 screening Methods 0.000 abstract description 5
- 210000000988 bone and bone Anatomy 0.000 description 29
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 24
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 24
- 238000007792 addition Methods 0.000 description 24
- 238000007747 plating Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 17
- 102100020880 Kit ligand Human genes 0.000 description 17
- 101710177504 Kit ligand Proteins 0.000 description 17
- 238000011534 incubation Methods 0.000 description 16
- 239000002243 precursor Substances 0.000 description 16
- 238000012546 transfer Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- 230000006907 apoptotic process Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000003394 haemopoietic effect Effects 0.000 description 14
- 102100031939 Erythropoietin Human genes 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000010354 integration Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000011773 genetically engineered mouse model Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 5
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000009509 drug development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000777 hematopoietic system Anatomy 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000000998 lymphohematopoietic effect Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- PBFKVYVGYHNCGT-UHFFFAOYSA-N 1-sulfanylpropane-1,2,3-triol Chemical compound OCC(O)C(O)S PBFKVYVGYHNCGT-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000007422 luminescence assay Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100022323 Drosophila melanogaster Marf gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100456970 Mus musculus Mfn2 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003343 megakaryocytopoietic effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027291 mitotic cell cycle Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000011527 multiparameter analysis Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical class NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40497202P | 2002-08-21 | 2002-08-21 | |
| US60/404,972 | 2002-08-21 | ||
| PCT/US2003/026167 WO2004018996A2 (en) | 2002-08-21 | 2003-08-21 | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2496251A1 true CA2496251A1 (en) | 2004-03-04 |
Family
ID=31946791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002496251A Abandoned CA2496251A1 (en) | 2002-08-21 | 2003-08-21 | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1539997A4 (de) |
| AU (1) | AU2003258319B2 (de) |
| CA (1) | CA2496251A1 (de) |
| WO (1) | WO2004018996A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7989178B2 (en) | 2001-01-29 | 2011-08-02 | Hemogenix, Inc. | Colony assay miniaturization with enumeration output |
| EP1364197B1 (de) | 2001-01-29 | 2010-04-14 | Ivan N. Rich | ATP-basierter Assay zur Bestimmung der Proliferation hämatopoetischer Stamm- und Vorläuferzellen |
| US7666615B2 (en) | 2001-01-29 | 2010-02-23 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
| US7354730B2 (en) | 2002-01-29 | 2008-04-08 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
| CN103827667B (zh) * | 2011-09-13 | 2016-07-13 | 巴斯夫欧洲公司 | 评估造血毒性的工具和方法 |
| EP4417210A1 (de) * | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Zusammensetzungen und verfahren für hämatopoetische stammzelltransplantate |
| WO2021013669A1 (en) * | 2019-07-24 | 2021-01-28 | Miltenyi Biotec B.V. & Co. KG | Assay for identifing colony-forming cells |
| CN115927169B (zh) * | 2022-10-11 | 2023-08-11 | 再造再生医学科技(杭州)有限公司 | 用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283179A (en) * | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
| US5733541A (en) * | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
| JPH10136978A (ja) * | 1996-11-08 | 1998-05-26 | Otsuka Pharmaceut Co Ltd | 造血幹細胞の培養方法 |
| US5854010A (en) * | 1997-03-10 | 1998-12-29 | Denison; Michael S. | Bioassay for detecting 2,3,7,8-tetrachlorodibenzo-para-dioxin and TCDD-like compounds and novel recombinant cell line useful therefor |
| EP1364197B1 (de) * | 2001-01-29 | 2010-04-14 | Ivan N. Rich | ATP-basierter Assay zur Bestimmung der Proliferation hämatopoetischer Stamm- und Vorläuferzellen |
-
2003
- 2003-08-21 AU AU2003258319A patent/AU2003258319B2/en not_active Ceased
- 2003-08-21 WO PCT/US2003/026167 patent/WO2004018996A2/en not_active Ceased
- 2003-08-21 CA CA002496251A patent/CA2496251A1/en not_active Abandoned
- 2003-08-21 EP EP03793209A patent/EP1539997A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004018996A2 (en) | 2004-03-04 |
| EP1539997A4 (de) | 2007-04-25 |
| AU2003258319A1 (en) | 2004-03-11 |
| EP1539997A2 (de) | 2005-06-15 |
| AU2003258319B2 (en) | 2009-09-17 |
| WO2004018996A3 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7700354B2 (en) | High throughput stem cell assay for identifying stem cells useful for transplantation | |
| US7883861B2 (en) | High throughput assay of hematopoietic stem and progenitor cell proliferation | |
| AU2002335610A1 (en) | High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation | |
| Chou et al. | On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology | |
| Srour et al. | Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro | |
| JP4099236B2 (ja) | 複数の細胞を培養し、その中の単個細胞の状態を決定する装置及び方法 | |
| Pessina et al. | Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials | |
| Mahalingaiah et al. | An in vitro model of hematotoxicity: differentiation of bone marrow–derived stem/progenitor cells into hematopoietic lineages and evaluation of lineage‐specific hematotoxicity | |
| Njoroge et al. | Characterization of viable autofluorescent macrophages among cultured peripheral blood mononuclear cells | |
| Miller et al. | Characterization of mouse hematopoietic stem and progenitor cells | |
| AU2003258319B2 (en) | High-throughput assay of hematopoietic stem and progenitor cell proliferation | |
| US20080248503A1 (en) | Methods of Screening Compounds to Predict Toxicity and Residual Proliferative and Differentiation Capacity of the Lympho-Hematopoietic System | |
| US7666615B2 (en) | High-throughput assay of hematopoietic stem and progenitor cell proliferation | |
| US20070087364A1 (en) | In vitro erythroid micronucleus assay for genotoxicity | |
| US7989178B2 (en) | Colony assay miniaturization with enumeration output | |
| US20090298102A1 (en) | Cell Potency Assay | |
| Spangrude | Characteristics of the hematopoietic stem cell compartment in adult mice | |
| WO2006052852A2 (en) | Kit for in process quality control to predict and determine engraftment and multilineage reconstitution potential of hematopoietic cells and cord blood storage | |
| Sarang et al. | Functional assessment of cord blood units using two different assays | |
| Srour et al. | Long-term generation and expansion of human primitive | |
| Young et al. | Quantitation of the proliferative potential of highly enriched human primitive hematopoietic progenitor cells using a stroma-free limiting dilution assay with automated scoring | |
| CA2335092A1 (en) | Method for identification and isolation of hematopoietic progenitor cells | |
| Edvardsson | Characterization of human myeloid progenitors and their differentiation | |
| WO2008151318A1 (en) | Colony assay miniaturization with enumeration output | |
| Snow | The role of STAT5 in hematolymphoid development in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |